Halifax Regional Police release Dartmouth suspect’s name and photo | SaltWire #news #novascotia - Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday.
Amgen's most advanced weight loss candidate, MariTide, does target incretins and is given by injection. It joins a compound designed to activate the GLP-1 hormone associated with a feeling of fullness to an antibody that blocks activity of a different gut hormone, GIP, that has been linked to fat storage and metabolic regulation.
Popular weight-loss drugs first used as diabetes treatments - Eli Lilly's Zepbound and Novo Nordisk's Wegovy, neither of which have been able to keep up with demand - are weekly injections that activate GLP-1. Zepbound is designed to also activate GIP. A large company like Amgen, despite being a later market entrant, has significant tools at its disposal to negotiate pricing and coverage terms with payers, he said.
Wegovy and Zepbound showed weight loss of 15% and 21%, respectively, in large trials that lasted more than a year.Shares of Amgen have fallen about 15% since early February, when full results of its 49-person MariTide study were published in a medical journal, including details on trial drop outs and high rates of nausea.
Year-to-date, Lilly's shares have gained 30% and Novo Nordisk's are up 25%. Both have become among the world's most valuable publicly traded companies due to explosive demand for their weight-loss drugs.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SaltWire Network - 🏆 45. / 63 Read more »
Source: SaltWire Network - 🏆 45. / 63 Read more »
Source: SaltWire Network - 🏆 45. / 63 Read more »
Source: SaltWire Network - 🏆 45. / 63 Read more »
Source: SaltWire Network - 🏆 45. / 63 Read more »
Source: SaltWire Network - 🏆 45. / 63 Read more »